A randomized phase 2 study of a human antiplatelet-derived growth factor α (PDGFRα) monoclonal antibody (olaratumab, IMC-3G3) with paclitaxel/carboplatin or paclitaxel/carboplatin alone in previously untreated patients with advanced non-small cell lung cancer (NSCLC).
David E. Gerber
No relevant relationships to disclose
Toby Christopher Campbell
Research Funding - ImClone Systems
Paul Swanson
No relevant relationships to disclose
Ariel Lopez-Chavez
Honoraria - Lilly
Lucas Wong
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Lilly
Afshin Dowlati
No relevant relationships to disclose
Amy Qin
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Jan G. C. E. Cosaert
Employment or Leadership Position - ImClone Systems
Maria Quintos Baggstrom
No relevant relationships to disclose